Biomerieux SA (BIOX)

Currency in EUR
72.85
+0.35(+0.48%)
Closed·
BIOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
72.5073.65
52 wk Range
65.60128.30
Key Statistics
Prev. Close
72.5
Open
72.6
Day's Range
72.5-73.65
52 wk Range
65.6-128.3
Volume
121.24K
Average Volume (3m)
185.17K
1-Year Change
-41.5798%
Book Value / Share
36.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
79.04
Upside
+8.50%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Biomerieux SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

4 Buy
9 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 79.04
(+8.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Hold75.00+2.95%78.00MaintainJul 30, 2026
UBS
Hold78.00+7.07%80.00MaintainJul 29, 2026
Barclays
Hold75.00+2.95%80.00MaintainJul 29, 2026
Kepler Cheuvreux
Buy85.00+16.68%-New CoverageJun 25, 2026
Barclays
Hold80.00+9.81%90.00MaintainJun 24, 2026

Biomerieux SA Earnings Call Summary for H1/2026

  • bioMérieux reported H1 2026 revenue of $981M, beating forecasts by 3.75%; shares rose 4.1% in premarket trading to $73.60.
  • Q2 organic growth rebounded to 5.0% after Q1's 3.9% decline; free cash flow surged 76% YoY to EUR 297M amid margin pressure.
  • SPOTFIRE platform posted strongest Q2 since launch with reagent sales up 40%; installed base reached 7,200 units, up 60% from prior year.
  • Management maintained 2026 guidance of 3-5% organic sales growth and 0-10% EBIT growth, citing respiratory season trends as key variable.
  • Company faces headwinds from Japan policy restrictions on SPOTFIRE, China microbiology weakness, and healthcare budget pressures across markets.
Last Updated: 2026-07-28, 09:30 a/m
Read Full Transcript

Earnings

Latest Release
Jul 28, 2026
EPS / Forecast
1.91 / --
Revenue / Forecast
981M / 945.57M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.90%
Dividend Yield
1.35%
Industry Median 1.99%
Annualized payout
0.98
Paid annually
5-Years Growth
+9.59%
Growth Streak

BIOX Income Statement

Compare BIOX to Peers and Sector

Metrics to compare
BIOX
Peers
Sector
Relationship
P/E Ratio
18.5x29.6x−0.4x
PEG Ratio
0.80−0.830.00
Price/Book
2.0x2.6x2.6x
Price / LTM Sales
2.1x3.6x3.0x
Upside (Analyst Target)
8.4%13.7%48.7%
Fair Value Upside
Unlock3.6%5.6%Unlock

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Employees
14894
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
19.61M16.66%1.43B
Other Institutional Investors
79.39M67.46%5.78B
Public Companies & Retail Investors
18.69M15.88%1.36B
Total
117.69M100.00%8.57B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Compagnie Merieux Alliance SAS59.24%69,720,2705,079,122
Giovanni Agnelli B.V.3.68%4,332,874315,650

People Also Watch

57.500
AMA
+1.81%
33.40
RUBF
+0.30%
140.20
LEGD
+0.83%
161.60
IPN
-0.19%
75.70
LTEN
+0.40%

FAQ

What Is the Biomerieux (BIOX) Stock Price Today?

The Biomerieux stock price today is 72.85 EUR.

What Stock Exchange Does Biomerieux Trade On?

Biomerieux is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Biomerieux?

The stock symbol for Biomerieux is "BIOX."

Does Biomerieux Pay Dividends? What’s The Current Dividend Yield?

The Biomerieux dividend yield is 1.35%.

What Is the Biomerieux Market Cap?

As of today, Biomerieux market cap is 8.57B EUR.

What Is Biomerieux's Earnings Per Share (TTM)?

The Biomerieux EPS (TTM) is 3.90.

When Is the Next Biomerieux Earnings Date?

Biomerieux will release its next earnings report on Oct 30, 2026.

From a Technical Analysis Perspective, Is BIOX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Biomerieux Stock Split?

Biomerieux has split 1 times.

How Many Employees Does Biomerieux Have?

Biomerieux has 14894 employees.

What is the current trading status of Biomerieux (BIOX)?

As of Aug 08, 2026, Biomerieux (BIOX) is trading at a price of 72.85 EUR, with a previous close of 72.50 EUR. The stock has fluctuated within a day range of 72.50 EUR to 73.65 EUR, while its 52-week range spans from 65.60 EUR to 128.30 EUR.

What Is Biomerieux (BIOX) Price Target According to Analysts?

The average 12-month price target for Biomerieux is 79.04 EUR, with a high estimate of 100 EUR and a low estimate of 64 EUR. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +8.50% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.